Century Therapeutics, Inc.
NASDAQ:IPSCBiotechnology
+$0.01 today
- Market cap
- $250.60M
- Beta
- 1.57
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.25
Volume 1.14M
Average 1.12M
IPSC Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Century Therapeutics, Inc.NASDAQ: IPSC
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $6.58M fell 21.8% year over year, ahead of the -32.4% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 588.2% from the prior quarter. Over 3 fiscal years it compounded at -9.0% a year.
Context
- Selling, general & admin amounted to 22.0% of revenue in FY2025, down 481.2 pp from a year earlier.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of $26.36M (+9.8%) for the fiscal year ending Dec 2026, a step up from the -27.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.58M+588.2% QoQ
- Last fiscal yearDec 2025
- $24M-27.6% YoY
- LTMMar 2026
- $22.18M-32.4% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 24M USD
- Year-over-year change
- -27.6%
- 4-year CAGR
- +13.1%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 24M | -27.6% |
| FY2024 | 2024-12-31 | 33.16M | -4.5% |
| FY2023 | 2023-12-31 | 34.71M | +8.9% |
| FY2022 | 2022-12-31 | 31.86M | +117.4% |
| FY2021 | 2021-12-31 | 14.65M | — |
Selling, General & Admin vs competitors
How IPSC compares with its peers on the latest reported figures
- IPSC's LTM Mar 2026 selling, general & admin of $22.18M is the 4th highest of the 8 companies compared; the peer median is $16.21M.
- Its year-over-year change of -32.4% is the 7th highest of 8, against a peer median of -1.4%.
- Over three fiscal years its annual growth of -9.0% compares with a peer median of +0.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $12.34B | +166786.7% | +2103.6% | — |
| LTM Mar 2026 | $104.54M | -7.7% | -10.2% | 69.2% | |
| LTM Mar 2026 | $38.12M | -1.4% | +24.4% | 11443.7% | |
| LTM Mar 2026 | $22.18M | -32.4% | -9.0% | — | |
| LTM Mar 2026 | $16.21M | +11.3% | +0.2% | 49.5% | |
| LTM Mar 2026 | $10.46M | -6.1% | -14.5% | — | |
| LTM Mar 2026 | $8.86M | +3.4% | -29.6% | 626.3% | |
| LTM Mar 2026 | $6.83M | -36.5% | +628.7% | — | |
| Peer median (excluding IPSC) | $16.21M | -1.4% | +0.2% | 347.7% | |
Competitors are the stored peer set for IPSC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 5.2M | 2.24M | 6.59M | 109.16M |
| Cost of Revenue | 4.58M | 0 | 0 | 0 | 13.1M |
| Gross Profit | (4.58M) | 5.2M | 2.24M | 6.59M | 96.06M |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 88.0% |
| Research & Development | 75.65M | 97.17M | 92.71M | 107.24M | 95.67M |
| Selling, General & Admin | 14.65M | 31.86M | 34.71M | 33.16M | 24M |
| Operating Expenses | 90.3M | 139.03M | 148.78M | 144.73M | 111.1M |
| Depreciation & Amortization | 4.58M | 8.44M | 13.04M | 13.3M | 13.1M |
| EBITDA | (89.92M) | (121.2M) | (121.21M) | (111.47M) | 3.45M |
| EBITDA Margin | — | -2331.2% | -5423.2% | -1691.8% | 3.2% |
| Operating Income | (94.88M) | (133.83M) | (146.55M) | (138.14M) | (15.04M) |
| Operating Margin | — | -2574.2% | -6556.9% | -2096.5% | -13.8% |
| Interest Income | 898K | 2.99M | 12.68M | 13.01M | 7.35M |
| Interest Expense | 1.28M | 0 | 540K | 0 | 0 |
| Other Income / Expenses | (898K) | 2.99M | 11.75M | 13.36M | 5.39M |
| Income Before Tax | (95.78M) | (130.84M) | (134.79M) | (124.78M) | (9.65M) |
| Pre-Tax Margin | — | -2516.7% | -6031.0% | -1893.7% | -8.8% |
| Income Tax Expense | 43K | 91K | 1.88M | 1.79M | (68K) |
| Net Income | (95.82M) | (130.93M) | (136.67M) | (126.57M) | (9.58M) |
| Net Margin | — | -2518.4% | -6115.1% | -1920.9% | -8.8% |
| EPS (Basic) | (1.74) | (2.27) | (2.30) | (1.61) | (0.11) |
| EPS (Diluted) | (1.74) | (2.27) | (2.30) | (1.61) | (0.11) |
| Weighted Avg Shares | 55.01M | 57.76M | 59.31M | 78.65M | 86.56M |
| Weighted Avg Shares (Diluted) | 55.01M | 57.76M | 59.31M | 78.65M | 86.56M |
Century Therapeutics, Inc.
NASDAQ:IPSC
Intrinsic Alpha fair value
Locked
Current Price
$1.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.